Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE1, PHASE2

Enrollment: 84

Sponsor: Ohio State University Comprehensive Cancer Center

Summary

This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.

Eligibility Criteria

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged 18 years or older 4. Early-stage breast cancer diagnosis (cT1-3 N0 or cT1-2 N1) and a Human Epidermal Receptor 2 (HER2)-positive or triple negative breast cancer (TNBC) tumor molecular subtype 5. Planning to receive neoadjuvant chemotherapy (NAC) and radiation therapy (RT) Exclusion Criteria: 1. Pregnancy or lactation 2. Inmate or prisoner 3. Treatment with an investigational drug or other intervention throughout their breast cancer treatment 4. Patients with skin involvement and/or distant metastases

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07217990). StuddyBuddy aggregates publicly available trial information.